Lakefront Biotherapeutics Sells Early-Stage CAR-T Programs to Armed Cell Therapeutics
Nemes Laszlo Lakefront Biotherapeutics (LKFT) has finalized the sale of its pre-clinical CAR-T programs for cancer treatment to Armed Cell Therapeutics. The transaction includes multi-targeting and armed CAR-T constructs aimed at enhancing potency, persistence, and preventing resistance in cancer therapies. This strategic move allows Lakefront to focus on other areas while leveraging Armed Cell's expertise in advancing these early-stage assets toward clinical development. The deal reflects growing interest in next-generation immunotherapies for oncology.
Topics: Biotech Cancer Treatment CAR-T